PHASE IB/II STUDY TO EVALUATE SAFETY AND EFFICACY OF DEBIO 0123 AND SACITUZUMAB GOVITECAN IN TNBC OR HR+/HER2- ADVANCED/ METASTATIC BREAST CANCER (WIN-B)

Status

Suspended

Phases

Phase 1Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-516322-60-00

Acronym

MEDOPP0621

Enrollment

Registered

2024-11-07

Start date

2025-01-17

Completion date

Unknown

Last updated

2025-10-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Triple-negative or hormonal receptor positive/human epidermal growth factor receptor 2 negative advanced/metastatic breast cancer., TRIPLE-NEGATIVE OR HR+/HER2– ADVANCED/METASTATIC BREAST CANCER

Interventions

None listed

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Countries

Spain

Outcome results